Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03721679
Title Poly-ICLC (Hiltonol) and Anti-PD1 or Anti-PD-L1
Recruitment Terminated
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Oncovir, Inc.
Indications

Advanced Solid Tumor

Therapies

Cemiplimab + Poly ICLC

Atezolizumab + Poly ICLC

Pembrolizumab + Poly ICLC

Durvalumab + Poly ICLC

Nivolumab + Poly ICLC

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.